We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-1.57 | -1.04% | 149.61 | 152.33 | 149.14 | 151.77 | 8,582,138 | 01:00:00 |
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Friday said is seeking approval from the European Medicines Agency for subcutaneous use of Darzalex in patients with multiple myeloma.
Darzalex is currently only approved for intravenous use.
Janssen said subcutaneous Darzalex is co-formulated with Halozyme Therapeutics Inc.'s (HALO) Enhanze drug-delivery technology.
Janssen last week filed for U.S. Food and Drug Administration approval for the subcutaneous formulation of Darzalex in multiple myeloma, a cancer that forms in a type of white blood cells called plasma cells and causes cancer cells to accumulate in the bone marrow.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 19, 2019 07:30 ET (11:30 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions